Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of gemcitabine + cisplatin + camrelizumab followed by IMRT with concurrent camrelizumab + cisplatin in newly treated metastatic nasopharyngeal carcinoma
ChiCTR2100046735Phase 2Recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoint: progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100046735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046735.